Dr. Rex Chin-Wei Yung on the Role of Pulmonology in Oncology

Abenacianine, a tumor-targeted fluorescent imaging agent, received fast track designation from the FDA after demonstrating its safety and efficacy in visualizing lung tumors in a phase 2 study.

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

The MARIPOSA study showed that the combination of amivantamab and lazertinib significantly improved overall survival over osimertinib in EGFR-mutated NSCLC.

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.

The phase 1 INSIGHT-003 trial of efti, pembrolizumab, and chemotherapy for first-line advanced nonsquamous NSCLC has completed enrollment.